A drug injection device contains a needle holder, an ejector, a needle member, and an actuation assembly. The needle holder defines a drug delivery direction extending toward the injection end. The ejector contains a fixing segment that is fixed to the needle holder and located in the drug delivery direction, and the abutting segment extending toward the injection end and protruding beyond the needle holder. The needle member is movably arranged relative to the needle holder and contains a needle shaft connected to a needle hub coaxially arranged with the ejector for the abutting segment inserting into the needle shaft. The actuator assembly connects the needle holder and the needle shaft for driving the needle member between a first position and a second position with respect to the needle holder.

This invention privilege patent belongs to the field of medicine and surgical instruments, and is intended to provide a new route of drug administration through needles plated with specific metals, aiming at better drug distribution and absorption upon administration, more precisely in the eyeball and/or on the patient's skin; to which the product has been originally improved in order to increase its efficacy in relation to other means of drug delivery known in the medical field, especially in skin, mucous and ocular diseases; it is an improvement that allows drug delivery to the skin and/or subcutaneous tissue, by means of a duly modified tattoo machine, which instead of ink, uses drugs, as a product to be inserted in the skin; in addition, this invention can be used to administer drugs directly to a person's eyeball, offering great practicality and agility to surgical procedures.

Systems and methods for monitoring eyedrop usage are disclosed. Example embodiments include a system to monitor eyedrop usage. The system may include a detection and activation circuit couplable to a wireless biosensor and an eyedrop dispenser. The detection and activation circuit may include a pressure transducer that transmits a signal upon detecting a force at, or above, a threshold value. The system may also include a wireless biosensor insertable into a region of an eyelid. The wireless biosensor may include a sensor to detect the physical change and the chemical change of tears as a result of eyedrop usage. The wireless biosensor may also include a transceiver to receive the signal that activates the sensor for an activation time.

Described here are systems and methods for accessing Schlemm's canal, for delivering a fluid composition therein, and for tearing the trabecular meshwork. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. The systems described here may be configured to cut or tear the trabecular meshwork with the body of an elongate member located within Schlemm's canal.

Embodiments disclosed herein generally relate to a stabilized intraocular drug delivery system for implantation into an eye of a subject. The system can include an intraocular lens (IOL) assembly and a drug delivery component. The IOL assembly can include a lens and a haptic. The haptic can include an outer end, an inner end opposite the outer end, a retention tab at the inner end, and a connection tab positioned between the outer end and the inner end and adjoining the lens. The drug delivery component can include at least one therapeutic agent and a fixation portion having an opening to receive the haptic and secure the drug delivery component to the IOL assembly. The fixation portion of the drug delivery component can be secured to the connection tab of the haptic such that the retention tab inhibits movement of the drug delivery component relative to the IOL assembly.

The present invention relates to a tip for use with delivery devices, particularly for use in implanting retinal implants into the retinal space of an eye. The tip includes a flexible envelope and an internal sliding member. Further, the invention relates to an inserter attachment and a delivery device including said tip.

Trypan Blue ophthalmic solutions are used to create and identify a landmark on the anterior capsule of an eye and thus identify a preferred location for an anterior capsulotomy during cataract surgery.

A device for dispensing a fluid drop-by-drop can include a fluid connector to supply the fluid to be dispensed, a pump which is fluidically connected to the fluid connector, an outlet nozzle which is fluidically connected to the pump, an actuating element, and a control unit. When the actuating element is actuated, the control unit activates the pump which pumps the supplied fluid to the outlet nozzle for dispensing drop-by-drop. The outlet nozzle has an outlet opening and a fluid channel which extends as far as the outlet opening and which, in the direction of the fluid from the pump as far as the outlet opening, has a first channel portion with a first cross-sectional surface and a second channel portion with a second cross-sectional surface adjoining the first channel portion. The second cross-sectional surface can be smaller than the first cross-sectional surface.

Methods and systems for performing an ophthalmic surgical treatment procedure include one or more wicking members to secure a volume of treatment fluid to a distal end of a surgical instrument. Such a surgical instrument may include an elongate tubular member having a proximal end, a distal end, and a lumen extending therebetween, the elongate tubular member being configured to penetrate a body cavity of a patient. The instrument may further include a wicking member extending beyond the distal end of the elongate tubular member. The wicking member may be configured to secure a volume of treatment fluid delivered through the lumen to the wicking member for application from the wicking member to target tissue in the body cavity.

The inner plug is mounted in an opening part of a container body and constitutes a nozzle part. The inner plug is constituted of a resin composite including a cyclic olefin copolymer and a polyethylene resin. A proportion of the cyclic olefin copolymer in 100 parts by weight of the resin composite is 25 to 85 parts by weight, a proportion of the polyethylene resin therein is 15 to 75 parts by weight, and a total amount of the cyclic olefin copolymer and the polyethylene resin is 80 to 100 parts by weight.